Pharsight

Viekira Xr patents expiration

VIEKIRA XR's oppositions filed in EPO

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8501238 ABBVIE Anti-infective agents and uses thereof
Sep, 2028

(4 years from now)

US8188104 ABBVIE Anti-infective agents and uses thereof
May, 2029

(4 years from now)

US8642538 ABBVIE Macrocyclic hepatitis C serine protease inhibitors
Sep, 2029

(5 years from now)

US8420596 ABBVIE Macrocyclic hepatitis C serine protease inhibitors
Apr, 2031

(6 years from now)

US8691938 ABBVIE Anti-viral compounds
Apr, 2032

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7148359 ABBVIE Polymorph of a pharmaceutical
Jul, 2019

(4 years ago)

US7364752 ABBVIE Solid dispersion pharamaceutical formulations
Nov, 2020

(3 years ago)

US8268349 ABBVIE Solid pharmaceutical dosage form
Aug, 2024

(2 months from now)

US8399015 ABBVIE Solid pharmaceutical dosage form
Aug, 2024

(2 months from now)

US9139536 ABBVIE Anti-infective agents and uses thereof
Nov, 2028

(4 years from now)

US9006387 ABBVIE Anti-viral compounds
Jun, 2030

(6 years from now)

US9044480 ABBVIE Compositions and methods for treating HCV
Apr, 2031

(6 years from now)

US8686026 ABBVIE Solid compositions
Jun, 2031

(7 years from now)

US10201584 ABBVIE Compositions and methods for treating HCV
May, 2032

(7 years from now)

US10201541 ABBVIE Compositions and methods for treating HCV
May, 2032

(7 years from now)

US8680106 ABBVIE Methods for treating HCV
Sep, 2032

(8 years from now)

US8685984 ABBVIE Methods for treating HCV
Sep, 2032

(8 years from now)

US8466159 ABBVIE Methods for treating HCV
Sep, 2032

(8 years from now)

US8492386 ABBVIE Methods for treating HCV
Sep, 2032

(8 years from now)

US10105365 ABBVIE Solid antiviral dosage forms
Jan, 2035

(10 years from now)

US9333204 ABBVIE Solid antiviral dosage forms
Jan, 2035

(10 years from now)

US9744170 ABBVIE Solid antiviral dosage forms
Jan, 2035

(10 years from now)

Viekira Xr is owned by Abbvie.

Viekira Xr contains Dasabuvir Sodium; Ombitasvir; Paritaprevir; Ritonavir.

Viekira Xr has a total of 22 drug patents out of which 2 drug patents have expired.

Expired drug patents of Viekira Xr are:

  • US7148359
  • US7364752

Viekira Xr was authorised for market use on 22 July, 2016.

Viekira Xr is available in tablet, extended release;oral dosage forms.

Viekira Xr can be used as treatment of hcv infection using paritaprevir, treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir, without ribavirin, treatment of hcv infection using dasabuvir, treatment of hcv infection using ombitasvir, use of dasabuvir to inhibit viral replication for the treatment of hcv infection., treatment of hcv infection using dasabuvir/ombitasvir/paritaprevir/ritonavir fixed dose combination, treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir with ribavirin..

Drug patent challenges can be filed against Viekira Xr from 19 December, 2018.

The generics of Viekira Xr are possible to be released after 02 January, 2035.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 19, 2019

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient

NCE-1 date:

19 December, 2018

Market Authorisation Date:

22 July, 2016

Treatment:

Treatment of hcv infection using dasabuvir; Treatment of hcv infection using ombitasvir; Treatment of hcv infection using paritaprevir; Treatment of hcv infection using dasabuvir/ombitasvir/paritaprev...

Dosage:

TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

VIEKIRA XR family patents

Family Patents